A part of MilliporeSigma

529685 | Prodigiosin Serratia marcescens - CAS 82-89-3 - Calbiochem

529685
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₂₀H₂₅N₃O 82-89-3

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      529685-200UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 200 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable tripyrrole alkaloid compound that displays immunosuppressive and anti-tumor properties irrespective of p53 status and multidrug resistance. Shown to selectively upregulate p21WAF/CIP1 and NAG-1 (nonsteroidal anti-inflammatory drug-activated gene 1) and downregulate survivin expression levels, induce mitochondria-mediated apoptosis and cell cycle arrest in tumor cells. Prevents FADD phosphorylation (IC50 = 2.0 µM in A549-FKR cells) through inhibition of FADD-kinase CK1α (IC50 ~ 6.0 µM in SW620-BGCR cells) and augments cisplatin (Cat. No. 232120)-induced apoptosis. Blocks NF-κB activation by decreasing pIκBα (by 63% at 3 µM) and IκBα levels in A549 cells, and shrinks tumor growth in A549-FKR tumor xenograft mouse model (3 mg/kg, i.p., o.d.).
          Catalogue Number529685
          Brand Family Calbiochem®
          SynonymsCasein Kinase I Inhibitor IV, 2-Methyl-3-pentyl-6-methoxyprodigiosene, NSC 47147
          References
          ReferencesSchinske, K.A., et al. 2011. Mol. Cancer Ther. 10, 1807.
          Chang, C.C., et al. 2011. J. Biosci. Bioeng. 5, 501
          Ho, T.F., et al. 2009. Toxicol. Appl. Pharmacol. 235, 253
          Soto-Cerrato, V., et al. 2007.Mol. Cancer Ther. 6, 362.
          Product Information
          CAS number82-89-3
          FormDark red solid
          Hill FormulaC₂₀H₂₅N₃O
          Chemical formulaC₂₀H₂₅N₃O
          Structure formula Image
          Applications
          Biological Information
          Purity≥95% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          529685

          References

          Reference overview
          Schinske, K.A., et al. 2011. Mol. Cancer Ther. 10, 1807.
          Chang, C.C., et al. 2011. J. Biosci. Bioeng. 5, 501
          Ho, T.F., et al. 2009. Toxicol. Appl. Pharmacol. 235, 253
          Soto-Cerrato, V., et al. 2007.Mol. Cancer Ther. 6, 362.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-June-2012 JSW
          SynonymsCasein Kinase I Inhibitor IV, 2-Methyl-3-pentyl-6-methoxyprodigiosene, NSC 47147
          DescriptionA cell-permeable tripyrrole alkaloid compound that displays immunosuppressive and anti-tumor properties irrespective of p53 status and multidrug resistance. Shown to selectively upregulate p21WAF/CIP1 and NAG-1 (nonsteroidal anti-inflammatory drug-activated gene 1) and downregulate survivin expression levels, induce mitochondria-mediated apoptosis and cell cycle arrest in tumor cells. Prevents FADD phosphorylation (IC50 = 2.0 µM in A549-FKR cells) through inhibition of FADD-kinase CK1α (IC50 ~ 6.0 µM in SW620-BGCR cells) and augments cisplatin (Cat. No. 232120)-induced apoptosis. Blocks NF-κB activation by decreasing pIκBα (by 63% at 3 µM) and IκBα levels in A549 cells, and shrinks tumor growth in A549-FKR tumor xenograft mouse model (3 mg/kg, i.p., o.d.).
          FormDark red solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number82-89-3
          Chemical formulaC₂₀H₂₅N₃O
          Structure formula
          Purity≥95% by HPLC
          SolubilityDMSO, DMF, EtOH, MeOH
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesSchinske, K.A., et al. 2011. Mol. Cancer Ther. 10, 1807.
          Chang, C.C., et al. 2011. J. Biosci. Bioeng. 5, 501
          Ho, T.F., et al. 2009. Toxicol. Appl. Pharmacol. 235, 253
          Soto-Cerrato, V., et al. 2007.Mol. Cancer Ther. 6, 362.